Report ID : 10151921 |
Published Date : 21 Oct 2022 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Market Overview:
Global Cancer Biotherapy Industry Market Research 2022-2030
"The worldwide cancer biotherapy market is anticipated to expand at a CAGR of 7% over the period 2022-2030, estimate to mark revenue of more than USD 100 billion by the end of 2021. The global cancer biotherapy market is expected to grow significantly due to the large number of patients. Other factors such as increasing prevalence of various cancers, increasing importance of biosimilars, anti-tumor patent expiry expected, and increasing demand for biological and pharmaceutical therapies will also affect market growth. Target.
Biomedicine uses experimental and various materials made from living organisms to treat some diseases. Biological therapies usually include interleukins, interferons, monoclonal antibodies, and vaccines. In biotherapy, the immune system is used directly or indirectly to fight cancer.
Some biological cancer treatments use vaccines and bacteria to stimulate the body's immune system and help fight cancer cells. Although some therapeutic agents contain antibodies, there are factors that prevent the market from growing into a global market, such as expensive drug manufacturing costs according to detailed government guidelines, side effects of anticancer drugs, and the risk of treatment failure. For example, they are classified as monoclonal antibodies, vaccines, cancer growth inhibitors, blood cell growth factors, and cytokines.
The monoclonal antibody fraction is also divided into naked monoclonal antibodies, conjugated monoclonal antibodies and two types of monoclonal antibodies. Vaccines are also classified as prophylactic and therapeutic vaccines. Cancer growth inhibitors are also classified as tyrosine kinase inhibitors, proteasome inhibitors, and mTOR inhibitors. Blood cell growth factors are also classified as lengrastim and filgrastim.
The cytokine segment is also classified as interferon and interleukin. Based on distribution channels, the global biologic cancer therapeutics market is segmented into hospital pharmacies, retail pharmacies, and post office pharmacies. Geographically, the global market is divided into Japan, Middle East & Africa, Latin America, Western Europe, Eastern Europe & North America, and North America excluding Asia Pacific including USA & Canada. .. Latin America consists of Mexico and Brazil.
The Western Europe region includes Germany, Italy, the United Kingdom, Spain, France, the Scandinavian countries and the Benelux countries. The Eastern Europe region includes Russia, Poland and other Eastern European countries. The Asia Pacific region includes Japan, China, India and ASEAN, excluding Australia and New Zealand. The Middle East and Africa region includes the GCC countries, South Africa, North Africa and other Middle East and Africa regions.
Geographically, North America holds a large share of the global cancer biology market. The North American market follows Europe, Asia and the Pacific. Growth drivers for the North American market include increased investment in research and development and government initiatives, rising disposable income, the presence of manufacturers of cancer and biological vaccines, affordable cancer treatment centers, and a growing number of health insurance companies. On the other hand, the Asia Pacific region is projected to grow at the fastest rate due to increased cancer incidence, increased patient focus and improved health care services. In the Asia Pacific region, Japan holds a large share of the cancer treatment market. Key players supporting the growth of the global biological cancer market include Amgen Inc., Bristol-Myers Squibb, Celgene Corporation and F. Hoffman-La Roche AG, Novartis International AG, Merck & Company, Inc., GlaxoSmithKline plc, Ellie Lilly There is Spectrum Pharmaceuticals. , Inc. Seattle Genetics, Inc. Etc"
Related Reports
Proof of Quality & Reliability
